12. The nanoparticle of claim **11**, wherein the small molecule chemotherapeutic is a camptothecin-based drug.

13. The nanoparticle of claim **10**, wherein the small molecule chemotherapeutic is attached to the first polymer through a biodegradable ester bond.

14. The nanoparticle of claim **1**, wherein:

(a) the first polymer comprises a mucic acid-containing polymer coupled to a nitrophenylboronic acid-containing polymer;

(b) the ligand for a first cellular receptor is Herceptin®; and

(c) the therapeutic agent is a camptothecin-based drug.

15. A pharmaceutical composition comprising the nanoparticle of claim **1** and a pharmaceutically acceptable vehicle, excipient or diluent.

16. A pharmaceutical composition comprising the nanoparticle of claim **14** and a pharmaceutically acceptable vehicle, excipient or diluent.

17. A method for treating a disease, disorder or condition in a subject, the method comprising administering the nanoparticle of claim **1** to the subject.

18. The method of claim **17**, wherein the disease, disorder or condition is cancer.

19. A method for treating a disease, disorder or condition in a subject, the method comprising administering the nanoparticle of claim **14** to the subject.

20. The method of claim **19**, wherein the disease, disorder or condition is cancer.

21. The nanoparticle of claim **1**, further comprising a ligand for a second cellular receptor.

22. The nanoparticle of **21** wherein the ligand for a second cellular receptor is a protein.

23. The nanoparticle of claim **22**, wherein the ligand for a second cellular receptor comprises transferrin.

24. The nanoparticle of claim **21**, wherein:

(a) the first polymer comprises a mucic acid-containing polymer coupled to a nitrophenylboronic acid-containing polymer;

(b) the ligand for a first cellular receptor is Herceptin®;

(c) the ligand for a second cellular comprises transferrin; and

(d) the therapeutic agent is a camptothecin-based drug.

25. A pharmaceutical composition comprising the nanoparticle of claim **21** and a pharmaceutically acceptable vehicle, excipient or diluent.

26. A pharmaceutical composition comprising the nanoparticle of claim **24** and a pharmaceutically acceptable vehicle, excipient or diluent.

27. A method for treating a disease, disorder or condition in a subject, the method comprising administering the nanoparticle of claim **21** to the subject.

28. The method of claim **27**, wherein the disease, disorder or condition is cancer.

29. A method for treating a disease, disorder or condition in a subject, the method comprising administering the nanoparticle of claim **24** to the subject.

30. The method of claim **29**, wherein the disease, disorder or condition is cancer.

31. A nanoparticle comprising:

(a) a first polymer containing a polyol coupled to a second polymer containing a phenylboronic acid;

(b) a first therapeutic agent; and

(c) a second therapeutic agent.

32. The nanoparticle of claim **31** wherein, in the first polymer, the polyol is a mucic acid polymer (MAP).

33. The nanoparticle of claim **32**, wherein the mucic acid polymer contains repeating units comprising:

(XXVII)



wherein:

n is 1.

34. The nanoparticle of claim **33**, wherein the mucic acid polymer has the structural unit:

(I)



derived from the coupling of A and B;

wherein A is

VI



B is

XIV



and

wherein:

sugar is mucic acid,

spacer is —CH_2—CH_2—NH—,

L is a leaving group, and

p is from 20-200.